Progressive Supranuclear Palsy 2017
“Progressive Supranuclear Palsy-Pipeline Insights, 2017�, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Progressive Supranuclear Palsy. This report provides information on the therapeutic development based on the Progressive Supranuclear Palsy dealing with all the pipeline drugs, comparative analysis at various stages covering Phase III, Phase II, Phase I and Pre clinical; therapeutics assessment by monotherapy products and molecule type drug information. It also features the discontinued products. The report covers financial information on companies involved in the therapeutic development for this indication. There is a separate section covering all the therapies under evaluation by various research institutes. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by team of industry experts. Secondary sources information and data has been collected from various printable and non-printable sources like search engines, news websites, government websites, trade journals, white papers, magazines, trade associations, books, industry portals, industry associations and available databases.